Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disordersAnnounced the expansion of patent protection for a broad range of molecules in its EVM301 portfolio, including five previously unannounced US patentsOut-licensed patented radiation dermatitis topical product to Aries Science & TechnologyOut-licensed EVM201 Program including EB-002 Candidate to MycoMedica Life Sciences CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.“The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastogenic molecule that is design
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint DiseaseBusiness Wire
- Enveric Biosciences Announces Closing of $5 Million Public OfferingBusiness Wire
- Enveric Biosciences Announces Pricing of $5 Million Public OfferingBusiness Wire
- Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office [Yahoo! Finance]Yahoo! Finance
ENVB
Sec Filings
- 2/5/25 - Form SCHEDULE
- 2/4/25 - Form SCHEDULE
- 2/4/25 - Form SCHEDULE
- ENVB's page on the SEC website